Biogen Inc. (NASDAQ:BIIB) was incorporated in 1997, originally under the name Biogen Idec, Inc. As a biopharmaceutical company, its central aims are to discover, develop, and manufacture products for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders.
The company has received growing attention over the last few weeks, as Biogen's investigational alzheimer's disease treatment (Aducanumab) was granted fast-track designation from the FDA. This event came on the heels of the company's decision to collaborate with Amyris to explore further uses of microbe engineering technology. Biogen has also enacted some significant managerial changes, as George Scangos elected to step-down from the CEO position and the company is showing intentions to spin off its Hemophilia business in an attempt to increase revenue numbers.
